Breaking News

Israeli Journal Admitted Into NIH Database

The Rambam Maimonides Medical Journal (RMMJ), a quarterly online medical research journal from Rambam Health Care Campus in Haifa, Israel, recently was entered into PubMed, an international database of life science and biomedical research maintained by the U.S. National Library of Medicine at the National Institutes of Health. PubMed entries include bibliographies and full research articles available for database search through a free online portal. According to its website, PubMed has at least 23 million citations available.

While many science and medical journals are available to subscribers only, RMMJ was created in July 2010 as a free platform for leading medical and science researchers from across the world to incorporate their articles and research into an online forum of expertise. RMMJ includes research and data on clinical studies related to patient care, disease prevention, public health, and laboratory and hospital innovations, as well as articles on medical ethics and current events in Israel and throughout the world. Entries are authored by internationally renowned researchers, including seven Nobel Prize winners.

“We want to deliver medicine with emotion and medicine with compassion,” said Professor Shraga Blazer, founder and editor of RMMJ and director of Rambam’s neonatal and infant intensive care unit. “The idea is to give access to medicine to the general public.” The journal has been read by at least 37,400 people in 137 countries. There have been approximately 157,600 downloaded articles from the site to date.

RMMJ’s inclusion in PubMed is sure to expand the reach of Israeli medical research and amplify the access to high-quality data for researchers, scientists, and practitioners around the world. v

Please ShareShare on FacebookTweet about this on TwitterShare on Google+Share on LinkedInShare on StumbleUponPin on PinterestEmail this to someone

Jewish Content

Posted by on September 13, 2013. Filed under In This Week's Edition. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.